The weekly litigation news digest is live. Subscribe now

IP Verse

Crystalline Forms Of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals - EP2134702

The patent EP2134702 was granted to Pfizer on Aug 30, 2023. The application was filed on Mar 25, 2008 under application number EP08719405A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2134702

PFIZER
Application Number
EP08719405A
Filing Date
Mar 25, 2008
Status
Patent Maintained As Amended
Jul 28, 2023
Publication Date
Aug 30, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
TEVA PHARMACEUTICALSFeb 27, 2018D YOUNGADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTUS2006094763
OPPOSITIONUS2006094763
OPPOSITIONUS2008274192
OPPOSITIONUS2014248347
OPPOSITIONWO0151919
OPPOSITIONWO2006048751
OPPOSITIONWO2006123223
OTHERUS2006094763
OTHERUS2008274192
OTHERWO2008122858

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents